C

CureVac NV
D

CVAC

5.50000
USD
0.01
(0.18%)
Post Trading
حجم التداول
844,611
الربح لكل سهم
-0
العائد الربحي
-
P/E
6
حجم السوق
1,238,450,120
أصول ذات صلة الأخبار المقالات

العنوان: CureVac NV

القطاع: Healthcare
الصناعة: Biotechnology
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.